Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FABP4 is a candidate marker of cerebellar liponeurocytomas.
Anghileri E, Eoli M, Paterra R, Ferroli P, Pollo B, Cuccarini V, Maderna E, Tringali G, Saini M, Salsano E, Finocchiaro G. Anghileri E, et al. Among authors: eoli m. J Neurooncol. 2012 Jul;108(3):513-9. doi: 10.1007/s11060-012-0853-0. Epub 2012 Apr 3. J Neurooncol. 2012. PMID: 22476608
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A. Di Stefano AL, et al. Among authors: eoli m. Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609060 Free PMC article. Clinical Trial.
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide.
Pellegatta S, Eoli M, Cuccarini V, Anghileri E, Pollo B, Pessina S, Frigerio S, Servida M, Cuppini L, Antozzi C, Cuzzubbo S, Corbetta C, Paterra R, Acerbi F, Ferroli P, DiMeco F, Fariselli L, Parati EA, Bruzzone MG, Finocchiaro G. Pellegatta S, et al. Among authors: eoli m. Oncoimmunology. 2018 Jan 29;7(4):e1412901. doi: 10.1080/2162402X.2017.1412901. eCollection 2018. Oncoimmunology. 2018. PMID: 29632727 Free PMC article.
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
Cuccarini V, Antelmi L, Pollo B, Paterra R, Calatozzolo C, Nigri A, DiMeco F, Eoli M, Finocchiaro G, Brenna G, Tramacere I, Bruzzone MG, Anghileri E. Cuccarini V, et al. Among authors: eoli m. Neurol Sci. 2020 Feb;41(2):347-355. doi: 10.1007/s10072-019-04087-9. Epub 2019 Oct 24. Neurol Sci. 2020. PMID: 31650436
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
Di Stefano AL, Picca A, Saragoussi E, Bielle F, Ducray F, Villa C, Eoli M, Paterra R, Bellu L, Mathon B, Capelle L, Bourg V, Gloaguen A, Philippe C, Frouin V, Schmitt Y, Lerond J, Leclerc J, Lasorella A, Iavarone A, Mokhtari K, Savatovsky J, Alentorn A, Sanson M; TARGET study group. Di Stefano AL, et al. Among authors: eoli m. Neuro Oncol. 2020 Nov 26;22(11):1614-1624. doi: 10.1093/neuonc/noaa121. Neuro Oncol. 2020. PMID: 32413119 Free PMC article.
147 results